Discovery and Characterization of R/S-N-3-Cyanophenyl-N'-(6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea, a New Histone Deacetylase Class III Inhibitor Exerting Antiproliferative Activity against Cancer Cell Lines
Schnekenburger, M; Goffin, Eric; Lee, J-Yet al.
2017 • In Journal of Medicinal Chemistry, 60 (11), p. 4714-4733
[en] A new series of N-aryl-N'-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)ureas bearing an alkoxycarbonylamino group at the 6-position were synthesized and examined as putative anticancer agents targeting sirtuins in glioma cells. On the basis of computational docking combined to in vitro sirtuin 1/2 inhibition assays, we selected compound 18 [R/S-N-3-cyanophenyl-N'-(6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea] which displays a potent antiproliferative activity on various glioma cell types, assessed by quantitative videomicroscopy, eventually triggering senescence. The impact on normal glial cells was lower with a selectivity index of >10. Furthermore, human U373 and Hs683 glioblastoma cell lines served to demonstrate the inhibitory activity of 18 against histone deacetylase (HDAC) class III sirtuins 1 and 2 (SIRT1/2) by quantifying acetylation levels of histone and non-histone proteins. The translational potential of 18 was validated by an NCI-60 cell line screen and validation of growth inhibition of drug resistant cancer cell models. Eventually, the anticancer potential of 18 was validated in 3D glioblastoma spheroids and in vivo by zebrafish xenografts. In summary, compound 18 is the first representative of a new class of SIRT inhibitors opening new perspectives in the medicinal chemistry of HDAC inhibitors.
Rogister, Bernard ; Université de Liège > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, et biochimie humaine
Bouider, N
Lefranc, F
Miklos, W
Mathieu, V
De Tullio, Pascal ; Université de Liège > Département de pharmacie > Chimie pharmaceutique
Kim, K-W
Dicato, Mario
Berger, W
Han, BW
Kiss, R
Pirotte, Bernard ; Université de Liège > Département de pharmacie > Chimie pharmaceutique
Discovery and Characterization of R/S-N-3-Cyanophenyl-N'-(6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea, a New Histone Deacetylase Class III Inhibitor Exerting Antiproliferative Activity against Cancer Cell Lines
Publication date :
08 June 2017
Journal title :
Journal of Medicinal Chemistry
ISSN :
0022-2623
eISSN :
1520-4804
Publisher :
American Chemical Society, Washington, United States - District of Columbia
DeLano, W. L. The PyMol Molecular Graphics System; DeLano Scientific: Palo Alto, CA, USA, 2002
Lefranc, F.; Brotchi, J.; Kiss, R. Possible future issues in the treatment of glioblastomas: Special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis J. Clin. Oncol. 2005, 23, 2411-2422 10.1200/JCO.2005.03.089
Stupp, R.; Hegi, M. E.; Mason, W. P.; van den Bent, M. J.; Taphoorn, M. J.; Janzer, R. C.; Ludwin, S. K.; Allgeier, A.; Fisher, B.; Belanger, K.; Hau, P.; Brandes, A. A.; Gijtenbeek, J.; Marosi, C.; Vecht, C. J.; Mokhtari, K.; Wesseling, P.; Villa, S.; Eisenhauer, E.; Gorlia, T.; Weller, M.; Lacombe, D.; Cairncross, J. G.; Mirimanoff, R. O. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase iii study: 5-year analysis of the eortc-ncic trial Lancet Oncol. 2009, 10, 459-466 10.1016/S1470-2045(09)70025-7
Cuperlovic-Culf, M.; Touaibia, M.; St-Coeur, P. D.; Poitras, J.; Morin, P.; Culf, A. S. Metabolic effects of known and novel hdac and sirt inhibitors in glioblastomas independently or combined with temozolomide Metabolites 2014, 4, 807-830 10.3390/metabo4030807
Folmer, F.; Orlikova, B.; Schnekenburger, M.; Dicato, M.; Diederich, M. Naturally occurring regulators of histone acetylation/deacetylation Curr. Nutr. Food Sci. 2010, 6, 78-99 10.2174/157340110790909581
Seidel, C.; Schnekenburger, M.; Dicato, M.; Diederich, M. Histone deacetylase modulators provided by mother nature Genes Nutr. 2012, 7, 357-367 10.1007/s12263-012-0283-9
Schnekenburger, M.; Florean, C.; Dicato, M.; Diederich, M. Epigenetic alterations as a universal feature of cancer hallmarks and a promising target for personalized treatments Curr. Top. Med. Chem. 2016, 16, 745-776 10.2174/1568026615666150825141330
Seidel, C.; Florean, C.; Schnekenburger, M.; Dicato, M.; Diederich, M. Chromatin-modifying agents in anti-cancer therapy Biochimie 2012, 94, 2264-2279 10.1016/j.biochi.2012.05.012
Mei, Z.; Zhang, X.; Yi, J.; Huang, J.; He, J.; Tao, Y. Sirtuins in metabolism, DNA repair and cancer J. Exp. Clin. Cancer Res. 2016, 35, 182 10.1186/s13046-016-0461-5
Carafa, V.; Rotili, D.; Forgione, M.; Cuomo, F.; Serretiello, E.; Hailu, G. S.; Jarho, E.; Lahtela-Kakkonen, M.; Mai, A.; Altucci, L. Sirtuin functions and modulation: From chemistry to the clinic Clin. Epigenet. 2016, 8, 61 10.1186/s13148-016-0224-3
Peck, B.; Chen, C. Y.; Ho, K. K.; Di Fruscia, P.; Myatt, S. S.; Coombes, R. C.; Fuchter, M. J.; Hsiao, C. D.; Lam, E. W. Sirt inhibitors induce cell death and p53 acetylation through targeting both sirt1 and sirt2 Mol. Cancer Ther. 2010, 9, 844-855 10.1158/1535-7163.MCT-09-0971
Sakkiah, S.; Arooj, M.; Kumar, M. R.; Eom, S. H.; Lee, K. W. Identification of inhibitor binding site in human sirtuin 2 using molecular docking and dynamics simulations PLoS One 2013, 8, e51429 10.1371/journal.pone.0051429
Trapp, J.; Jochum, A.; Meier, R.; Saunders, L.; Marshall, B.; Kunick, C.; Verdin, E.; Goekjian, P.; Sippl, W.; Jung, M. Adenosine mimetics as inhibitors of nad+-dependent histone deacetylases, from kinase to sirtuin inhibition J. Med. Chem. 2006, 49, 7307-7316 10.1021/jm060118b
Medda, F.; Russell, R. J.; Higgins, M.; McCarthy, A. R.; Campbell, J.; Slawin, A. M.; Lane, D. P.; Lain, S.; Westwood, N. J. Novel cambinol analogs as sirtuin inhibitors: Synthesis, biological evaluation, and rationalization of activity J. Med. Chem. 2009, 52, 2673-2682 10.1021/jm8014298
Outeiro, T. F.; Kontopoulos, E.; Altmann, S. M.; Kufareva, I.; Strathearn, K. E.; Amore, A. M.; Volk, C. B.; Maxwell, M. M.; Rochet, J. C.; McLean, P. J.; Young, A. B.; Abagyan, R.; Feany, M. B.; Hyman, B. T.; Kazantsev, A. G. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease Science 2007, 317, 516-519 10.1126/science.1143780
Kim, H. W.; Kim, S. A.; Ahn, S. G. Sirtuin inhibitors, ex527 and agk2, suppress cell migration by inhibiting hsf1 protein stability Oncol. Rep. 2016, 35, 235-242 10.3892/or.2015.4381
Florence, X.; Dilly, S.; de Tullio, P.; Pirotte, B.; Lebrun, P. Modulation of the 6-position of benzopyran derivatives and inhibitory effects on the insulin releasing process Bioorg. Med. Chem. 2011, 19, 3919-3928 10.1016/j.bmc.2011.05.040
Khelili, S.; Florence, X.; Bouhadja, M.; Abdelaziz, S.; Mechouch, N.; Mohamed, Y.; de Tullio, P.; Lebrun, P.; Pirotte, B. Synthesis and activity on rat aorta rings and rat pancreatic beta-cells of ring-opened analogues of benzopyran-type potassium channel activators Bioorg. Med. Chem. 2008, 16, 6124-6130 10.1016/j.bmc.2008.04.043
Ma, L.; Maruwge, W.; Strambi, A.; D'Arcy, P.; Pellegrini, P.; Kis, L.; de Milito, A.; Lain, S.; Brodin, B. Sirt1 and sirt2 inhibition impairs pediatric soft tissue sarcoma growth Cell Death Dis. 2014, 5, e1483 10.1038/cddis.2014.385
Trott, O.; Olson, A. J. Autodock vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading J. Comput. Chem. 2010, 31, 455-461 10.1002/jcc.21334
Rumpf, T.; Schiedel, M.; Karaman, B.; Roessler, C.; North, B. J.; Lehotzky, A.; Olah, J.; Ladwein, K. I.; Schmidtkunz, K.; Gajer, M.; Pannek, M.; Steegborn, C.; Sinclair, D. A.; Gerhardt, S.; Ovadi, J.; Schutkowski, M.; Sippl, W.; Einsle, O.; Jung, M. Selective sirt2 inhibition by ligand-induced rearrangement of the active site Nat. Commun. 2015, 6, 6263 10.1038/ncomms7263
Moniot, S.; Schutkowski, M.; Steegborn, C. Crystal structure analysis of human sirt2 and its adp-ribose complex J. Struct. Biol. 2013, 182, 136-143 10.1016/j.jsb.2013.02.012
Finnin, M. S.; Donigian, J. R.; Pavletich, N. P. Structure of the histone deacetylase sirt2 Nat. Struct. Biol. 2001, 8, 621-625 10.1038/89668
Schiedel, M.; Rumpf, T.; Karaman, B.; Lehotzky, A.; Olah, J.; Gerhardt, S.; Ovadi, J.; Sippl, W.; Einsle, O.; Jung, M. Aminothiazoles as potent and selective sirt2 inhibitors: A structure-activity relationship study J. Med. Chem. 2016, 59, 1599-1612 10.1021/acs.jmedchem.5b01517
Davenport, A. M.; Huber, F. M.; Hoelz, A. Structural and functional analysis of human sirt1 J. Mol. Biol. 2014, 426, 526-541 10.1016/j.jmb.2013.10.009
Dai, H.; Case, A. W.; Riera, T. V.; Considine, T.; Lee, J. E.; Hamuro, Y.; Zhao, H.; Jiang, Y.; Sweitzer, S. M.; Pietrak, B.; Schwartz, B.; Blum, C. A.; Disch, J. S.; Caldwell, R.; Szczepankiewicz, B.; Oalmann, C.; Yee Ng, P.; White, B. H.; Casaubon, R.; Narayan, R.; Koppetsch, K.; Bourbonais, F.; Wu, B.; Wang, J.; Qian, D.; Jiang, F.; Mao, C.; Wang, M.; Hu, E.; Wu, J. C.; Perni, R. B.; Vlasuk, G. P.; Ellis, J. L. Crystallographic structure of a small molecule sirt1 activator-enzyme complex Nat. Commun. 2015, 6, 7645 10.1038/ncomms8645
Cao, D.; Wang, M.; Qiu, X.; Liu, D.; Jiang, H.; Yang, N.; Xu, R. M. Structural basis for allosteric, substrate-dependent stimulation of sirt1 activity by resveratrol Genes Dev. 2015, 29, 1316-1325 10.1101/gad.265462.115
Zhao, X.; Allison, D.; Condon, B.; Zhang, F.; Gheyi, T.; Zhang, A.; Ashok, S.; Russell, M.; MacEwan, I.; Qian, Y.; Jamison, J. A.; Luz, J. G. The 2.5 a crystal structure of the sirt1 catalytic domain bound to nicotinamide adenine dinucleotide (nad+) and an indole (ex527 analogue) reveals a novel mechanism of histone deacetylase inhibition J. Med. Chem. 2013, 56, 963-969 10.1021/jm301431y
Sayd, S.; Thirant, C.; El-Habr, E. A.; Lipecka, J.; Dubois, L. G.; Bogeas, A.; Tahiri-Jouti, N.; Chneiweiss, H.; Junier, M. P. Sirtuin-2 activity is required for glioma stem cell proliferation arrest but not necrosis induced by resveratrol Stem Cell Rev. 2014, 10, 103-113 10.1007/s12015-013-9465-0
Seidel, C.; Schnekenburger, M.; Dicato, M.; Diederich, M. Histone deacetylase 6 in health and disease Epigenomics 2015, 7, 103-118 10.2217/epi.14.69
Lefranc, F.; Nuzzo, G.; Hamdy, N. A.; Fakhr, I.; Moreno Y Banuls, L.; Van Goietsenoven, G.; Villani, G.; Mathieu, V.; van Soest, R.; Kiss, R.; Ciavatta, M. L. In vitro pharmacological and toxicological effects of norterpene peroxides isolated from the red sea sponge diacarnus erythraeanus on normal and cancer cells J. Nat. Prod. 2013, 76, 1541-1547 10.1021/np400107t
Branle, F.; Lefranc, F.; Camby, I.; Jeuken, J.; Geurts-Moespot, A.; Sprenger, S.; Sweep, F.; Kiss, R.; Salmon, I. Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in c6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy Cancer 2002, 95, 641-655 10.1002/cncr.10710
Grandjenette, C.; Schnekenburger, M.; Karius, T.; Ghelfi, J.; Gaigneaux, A.; Henry, E.; Dicato, M.; Diederich, M. 5-aza-2′-deoxycytidine-mediated c-myc down-regulation triggers telomere-dependent senescence by regulating human telomerase reverse transcriptase in chronic myeloid leukemia Neoplasia 2014, 16, 511-528 10.1016/j.neo.2014.05.009
Wang, X.; Simpson, E. R.; Brown, K. A. P53: Protection against tumor growth beyond effects on cell cycle and apoptosis Cancer Res. 2015, 75, 5001-5007 10.1158/0008-5472.CAN-15-0563
Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: Role of atp-dependent transporters Nat. Rev. Cancer 2002, 2, 48-58 10.1038/nrc706
Yen, Y.; Grill, S. P.; Dutschman, G. E.; Chang, C. N.; Zhou, B. S.; Cheng, Y. C. Characterization of a hydroxyurea-resistant human kb cell line with supersensitivity to 6-thioguanine Cancer Res. 1994, 54, 3686-3691
Schuttelkopf, A. W.; van Aalten, D. M. Prodrg: A tool for high-throughput crystallography of protein-ligand complexes Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 1355-1363 10.1107/S0907444904011679
Laskowski, R. A.; Swindells, M. B. Ligplot+: Multiple ligand-protein interaction diagrams for drug discovery J. Chem. Inf. Model. 2011, 51, 2778-2786 10.1021/ci200227u
Le Mercier, M.; Fortin, S.; Mathieu, V.; Roland, I.; Spiegl-Kreinecker, S.; Haibe-Kains, B.; Bontempi, G.; Decaestecker, C.; Berger, W.; Lefranc, F.; Kiss, R. Galectin 1 proangiogenic and promigratory effects in the hs683 oligodendroglioma model are partly mediated through the control of bex2 expression Neoplasia 2009, 11, 485-496 10.1593/neo.81526
Torsvik, A.; Stieber, D.; Enger, P. O.; Golebiewska, A.; Molven, A.; Svendsen, A.; Westermark, B.; Niclou, S. P.; Olsen, T. K.; Chekenya Enger, M.; Bjerkvig, R. U-251 revisited: Genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells Cancer Med. 2014, 3, 812-824 10.1002/cam4.219
Stein, G. H. T98g: An anchorage-independent human tumor cell line that exhibits stationary phase g1 arrest in vitro J. Cell. Physiol. 1979, 99, 43-54 10.1002/jcp.1040990107
Roninson, I. B.; Chin, J. E.; Choi, K. G.; Gros, P.; Housman, D. E.; Fojo, A.; Shen, D. W.; Gottesman, M. M.; Pastan, I. Isolation of human mdr DNA sequences amplified in multidrug-resistant kb carcinoma cells Proc. Natl. Acad. Sci. U. S. A. 1986, 83, 4538-4542 10.1073/pnas.83.12.4538
Bunz, F.; Dutriaux, A.; Lengauer, C.; Waldman, T.; Zhou, S.; Brown, J. P.; Sedivy, J. M.; Kinzler, K. W.; Vogelstein, B. Requirement for p53 and p21 to sustain g2 arrest after DNA damage Science 1998, 282, 1497-1501 10.1126/science.282.5393.1497
Schuurhuis, G. J.; Broxterman, H. J.; de Lange, J. H.; Pinedo, H. M.; van Heijningen, T. H.; Kuiper, C. M.; Scheffer, G. L.; Scheper, R. J.; van Kalken, C. K.; Baak, J. P.; Lankelma, J. Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of p-glycoprotein Br. J. Cancer 1991, 64, 857-861 10.1038/bjc.1991.413
Schnekenburger, M.; Grandjenette, C.; Ghelfi, J.; Karius, T.; Foliguet, B.; Dicato, M.; Diederich, M. Sustained exposure to the DNA demethylating agent, 2′-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy Biochem. Pharmacol. 2011, 81, 364-378 10.1016/j.bcp.2010.10.013
Goffin, E.; Lamoral-Theys, D.; Tajeddine, N.; de Tullio, P.; Mondin, L.; Lefranc, F.; Gailly, P.; Rogister, B.; Kiss, R.; Pirotte, B. N-aryl-n′-(chroman-4-yl)ureas and thioureas display in vitro anticancer activity and selectivity on apoptosis-resistant glioblastoma cells: Screening, synthesis of simplified derivatives, and structure-activity relationship analysis Eur. J. Med. Chem. 2012, 54, 834-844 10.1016/j.ejmech.2012.06.050
Frederick, R.; Bruyere, C.; Vancraeynest, C.; Reniers, J.; Meinguet, C.; Pochet, L.; Backlund, A.; Masereel, B.; Kiss, R.; Wouters, J. Novel trisubstituted harmine derivatives with original in vitro anticancer activity J. Med. Chem. 2012, 55, 6489-6501 10.1021/jm300542e
Mathieu, V.; Chantome, A.; Lefranc, F.; Cimmino, A.; Miklos, W.; Paulitschke, V.; Mohr, T.; Maddau, L.; Kornienko, A.; Berger, W.; Vandier, C.; Evidente, A.; Delpire, E.; Kiss, R. Sphaeropsidin a shows promising activity against drug-resistant cancer cells by targeting regulatory volume increase Cell. Mol. Life Sci. 2015, 72, 3731-3746 10.1007/s00018-015-1902-6
Mathieu, V.; Van Den Berge, E.; Ceusters, J.; Konopka, T.; Cops, A.; Bruyere, C.; Pirker, C.; Berger, W.; Trieu-Van, T.; Serteyn, D.; Kiss, R.; Robiette, R. New 5-aryl-1h-imidazoles display in vitro antitumor activity against apoptosis-resistant cancer models, including melanomas, through mitochondrial targeting J. Med. Chem. 2013, 56, 6626-6637 10.1021/jm400287v
Seidel, C.; Schnekenburger, M.; Mazumder, A.; Teiten, M. H.; Kirsch, G.; Dicato, M.; Diederich, M. 4-hydroxybenzoic acid derivatives as hdac6-specific inhibitors modulating microtubular structure and hsp90alpha chaperone activity against prostate cancer Biochem. Pharmacol. 2016, 99, 31-52 10.1016/j.bcp.2015.11.005
Piccinini, F.; Tesei, A.; Arienti, C.; Bevilacqua, A. Cancer multicellular spheroids: Volume assessment from a single 2d projection Comput. Methods Programs Biomed. 2015, 118, 95-106 10.1016/j.cmpb.2014.12.003
Florean, C.; Schnekenburger, M.; Lee, J. Y.; Kim, K. R.; Mazumder, A.; Song, S.; Kim, J. M.; Grandjenette, C.; Kim, J. G.; Yoon, A. Y.; Dicato, M.; Kim, K. W.; Christov, C.; Han, B. W.; Proksch, P.; Diederich, M. Discovery and characterization of isofistularin-3, a marine brominated alkaloid, as a new DNA demethylating agent inducing cell cycle arrest and sensitization to trail in cancer cells Oncotarget 2016, 7, 24027-24049 10.18632/oncotarget.8210
El Amrani, M.; Lai, D.; Debbab, A.; Aly, A. H.; Siems, K.; Seidel, C.; Schnekenburger, M.; Gaigneaux, A.; Diederich, M.; Feger, D.; Lin, W.; Proksch, P. Protein kinase and hdac inhibitors from the endophytic fungus epicoccum nigrum J. Nat. Prod. 2014, 77, 49-56 10.1021/np4005745
Seidel, C.; Schnekenburger, M.; Dicato, M.; Diederich, M. Antiproliferative and proapoptotic activities of 4-hydroxybenzoic acid-based inhibitors of histone deacetylases Cancer Lett. 2014, 343, 134-146 10.1016/j.canlet.2013.09.026
Nunes, M. J.; Milagre, I.; Schnekenburger, M.; Gama, M. J.; Diederich, M.; Rodrigues, E. Sp proteins play a critical role in histone deacetylase inhibitor-mediated derepression of cyp46a1 gene transcription J. Neurochem. 2010, 113, 418-431 10.1111/j.1471-4159.2010.06612.x
Karius, T.; Schnekenburger, M.; Ghelfi, J.; Walter, J.; Dicato, M.; Diederich, M. Reversible epigenetic fingerprint-mediated glutathione-s-transferase p1 gene silencing in human leukemia cell lines Biochem. Pharmacol. 2011, 81, 1329-1342 10.1016/j.bcp.2011.03.014
Pirotte, B.; Florence, X.; Goffin, E.; Medeiros, M. B.; de Tullio, P.; Lebrun, P. 4-phenylureido/thioureido-substituted 2,2-dimethylchroman analogs of cromakalim bearing a bulky "carbamate" moiety at the 6-position as potent inhibitors of glucose-sensitive insulin secretion Eur. J. Med. Chem. 2016, 121, 338-351 10.1016/j.ejmech.2016.05.042
